Avanir Pharmaceuticals Stock Rating Reaffirmed by Canaccord Genuity (AVNR)
Posted by LUSA Staff on Nov 28th, 2012 // No Comments
Avanir Pharmaceuticals (NASDAQ: AVNR)‘s stock had its “buy” rating restated by analysts at Canaccord Genuity in a research report issued to clients and investors on Wednesday.
Separately, analysts at Cowen initiated coverage on shares of Avanir Pharmaceuticals in a research note to investors on Monday, October 1st. They set an “outperform” rating on the stock.
Avanir Pharmaceuticals traded up 5.08% on Wednesday, hitting $2.795. Avanir Pharmaceuticals has a 1-year low of $1.77 and a 1-year high of $4.05. The company’s market cap is $380.6 million.
Sentiment: Strong Buy